In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
Click arrow to play Download TWiV 1004 (32 MB .mp3, 53 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- FDA approves Arexvy, the first RSV vaccine approved in the US (FDA) 2:05
- Association between SARS-CoV-2 and content of samples from the Huanan Seafood Market (bioRxiv) 5:57
- Researchers disagree over how bad it is to be reinfected with COVID-19 and lasting changes to the immune system (Nature) 10:39
- Virtual care and emergency department use during the COVID-19 Pandemic among patients of family physicians (JAMA) 13:04
- Vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers (NEJM) 21:45
- NVX-CoV2373 vaccine efficacy against hospitalization (Vaccine) 23:42
- Comparative effectiveness of the SARS-COV-2 vaccines during Delta (Cell) 25:14
- Assessment of gender-specific COVID-19 case fatality risk (JAMA) 28:49
- Clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir (JAMA) 31:27
- Timing of intubation and ICU mortality in COVID-19 patients (BMC) 34:50
- Real-life experience with Remdesivir for treatment of COVID-19 (JAC) 37:13
- Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA (Frontiers) 38:31
- Contribute to our FIMRC fundraiser at PWB 42:03
- Letters read on TWiV 1004 43:55
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Leave a Reply